BACKGROUND: Langerhans cells (LCs) are self-renewing epidermal myeloid cells that can migrate and mature into dendritic cells. Recipient LCs that survive cytotoxic therapy given in preparation for allogeneic hematopoietic cell transplantation may prime donor T cells to mediate cutaneous graft-versus-host disease (GVHD). This possible association, however, has not been investigated in the setting of nonmyeloablative allografting. METHODS: We prospectively studied the kinetics of LC-chimerism after sex-mismatched allogeneic hematopoietic cell transplantation with nonmyeloablative (n=23) or myeloablative (n=25) conditioning. Combined XY-FISH and Langerin-staining was used to assess donor LC-chimerism in skin biopsies obtained on days 28, 56, and 84 after transplant. The degree of donor LC-chimerism was correlated with the development of skin GVHD. RESULTS: We observed significantly delayed donor LC-engraftment after nonmyeloablative transplantation compared with other hematopoietic compartments and compared with LC-engraftment after myeloablative conditioning. In most recipients of nonmyeloablative transplants, recipient LCs proliferated in situ, recruitment of donor-LCs was delayed by two months, and full donor LC-chimerism was only reached by day 84 after transplant. Although persistence of host LCs on day-28 after transplant was not predictive for acute or chronic skin GVHD, the recruitment of donor-derived LCs was associated with nonspecific inflammatory infiltrates (P=0.009). CONCLUSIONS: These results show that LCs can self-renew locally but are replaced by circulating precursors even after minimally toxic nonmyeloablative transplant conditioning. Cutaneous inflammation accompanies donor LC-engraftment, but differences in LC conversion-kinetics do not predict clinical or histopathological GVHD.
BACKGROUND: Langerhans cells (LCs) are self-renewing epidermal myeloid cells that can migrate and mature into dendritic cells. Recipient LCs that survive cytotoxic therapy given in preparation for allogeneic hematopoietic cell transplantation may prime donor T cells to mediate cutaneous graft-versus-host disease (GVHD). This possible association, however, has not been investigated in the setting of nonmyeloablative allografting. METHODS: We prospectively studied the kinetics of LC-chimerism after sex-mismatched allogeneic hematopoietic cell transplantation with nonmyeloablative (n=23) or myeloablative (n=25) conditioning. Combined XY-FISH and Langerin-staining was used to assess donor LC-chimerism in skin biopsies obtained on days 28, 56, and 84 after transplant. The degree of donor LC-chimerism was correlated with the development of skin GVHD. RESULTS: We observed significantly delayed donor LC-engraftment after nonmyeloablative transplantation compared with other hematopoietic compartments and compared with LC-engraftment after myeloablative conditioning. In most recipients of nonmyeloablative transplants, recipient LCs proliferated in situ, recruitment of donor-LCs was delayed by two months, and full donor LC-chimerism was only reached by day 84 after transplant. Although persistence of host LCs on day-28 after transplant was not predictive for acute or chronic skin GVHD, the recruitment of donor-derived LCs was associated with nonspecific inflammatory infiltrates (P=0.009). CONCLUSIONS: These results show that LCs can self-renew locally but are replaced by circulating precursors even after minimally toxic nonmyeloablative transplant conditioning. Cutaneous inflammation accompanies donor LC-engraftment, but differences in LC conversion-kinetics do not predict clinical or histopathological GVHD.
Authors: Nadira Durakovic; Karl B Bezak; Mario Skarica; Vedran Radojcic; Ephraim J Fuchs; George F Murphy; Leo Luznik Journal: J Immunol Date: 2006-10-01 Impact factor: 5.422
Authors: Susanne Auffermann-Gretzinger; Lars Eger; Martin Bornhäuser; Knut Schäkel; Uta Oelschlaegel; Markus Schaich; Thomas Illmer; Christian Thiede; Gerhard Ehninger Journal: Transplantation Date: 2006-03-27 Impact factor: 4.939
Authors: R A Nash; R Etzioni; R Storb; T Furlong; T Gooley; C Anasetti; F R Appelbaum; K Doney; P Martin; J Slattery Journal: Blood Date: 1995-06-15 Impact factor: 22.113
Authors: R Storb; H J Deeg; J Whitehead; F Appelbaum; P Beatty; W Bensinger; C D Buckner; R Clift; K Doney; V Farewell Journal: N Engl J Med Date: 1986-03-20 Impact factor: 91.245
Authors: Matthew P Collin; Derek N J Hart; Graham H Jackson; Gordon Cook; James Cavet; Stephen Mackinnon; Peter G Middleton; Anne M Dickinson Journal: J Exp Med Date: 2006-01-03 Impact factor: 14.307
Authors: C L Stewart; C M Cornejo; K A Wanat; I Sander; S Samimi; S Prouty; J Seykora; P Zhang; M Rosenbach; E J Kim; R G Micheletti Journal: Br J Dermatol Date: 2018-01-08 Impact factor: 9.302
Authors: Roland Reibke; Katja Anslinger; Dagmar von Máriássy; Mareike Verbeek; Britta Gätjens; Roberta Schiller Journal: Int J Legal Med Date: 2022-06-03 Impact factor: 2.686